Management of Chronic Heart Failure in Adults: Synopsis of the National Institute for Health and Cli...
Download
1 / 14

Management of Chronic Heart Failure in Adults: Synopsis of the National Institute for Health and Clinical Excellence Gui - PowerPoint PPT Presentation


  • 129 Views
  • Uploaded on

Management of Chronic Heart Failure in Adults: Synopsis of the National Institute for Health and Clinical Excellence Guideline . Jonathan Mant , MD; abdallah al- mohammad , md ; Sharon Swain, BA, Phd ; and philippe laramee,dc,msc , for the guideline development group

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Management of Chronic Heart Failure in Adults: Synopsis of the National Institute for Health and Clinical Excellence Gui' - malachi


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

Management of Chronic Heart Failure in Adults: Synopsis of the National Institute for Health and Clinical Excellence Guideline

Jonathan Mant, MD; abdallah al-mohammad, md; Sharon Swain, BA, Phd; and philippelaramee,dc,msc, for the guideline development group

Chris fontimayor ms-III

Mercer University

School of medicine

Dr. Rahimi

9/9/2011


Heart failure hf
Heart Failure (HF) the National Institute for Health and Clinical Excellence Guideline

  • A common clinical syndrome representing the end-stage of a number of different cardiac diseases

  • Result of any structural or functional cardiac disorder that impairs the ability of the ventricle to fill with or eject blood

  • Two types

    • Systolic Dysfunction

    • Diastolic Dysfunction


Heart failure
Heart Failure the National Institute for Health and Clinical Excellence Guideline

  • Symptoms – dyspnea, orthopnea, paroxysmal nocturnal dyspnea, nocturnal cough, confusion and memory loss in advanced stages, diaphoresis and cool extremities at rest

  • New York Heart Association (NYHA) Classification

    • Class I – symptoms only with vigorous activities

    • Class II – symptoms with moderate exertion

    • Class III – symptoms with normal daily activities

    • Class IV – symptoms at rest


National institute for health and clinical excellence nice
National Institute for Health and Clinical Excellence (NICE) the National Institute for Health and Clinical Excellence Guideline

  • Develops clinical practice guidelines for the National Health Service of England and Wales

  • First guideline on HF in 2003

  • Target population: Non-pregnant adults with symptoms of chronic HF

  • Exclusion: Patients with acute HF or acute exacerbations of chronic HF

  • Updated every 3 years

    • Literature searches for new evidence, warnings from licensing agencies , and major changes in costs

    • Actively seek out the views of health care professionals and patients


Guideline development process
Guideline Development Process the National Institute for Health and Clinical Excellence Guideline

  • Guideline development group (GDG)– general practitioners, specialist nurses, a consultant physician, consultant cardiologists, and 2 members representing patients and caregivers

  • Clinical question Literature review Evidence grading


High quality evidence for pharmacologic therapy
High Quality Evidence for Pharmacologic Therapy the National Institute for Health and Clinical Excellence Guideline

  • ACE inhibitors and ß-blockers reduce morbidity and increase survival in patients with left ventricular systolic dysfunction

  • No difference exists between selective ß-blockers (ie metoprolol) and nonselective ß-blockers (ie carvedilol) on the combined end point of mortality and hospitalization

  • Combination therapy of ARBs and ACE inhibitors increases risk of hyperkalemia

  • Adding ARB to ACE inhibitor and ß-blocker reduces the mortality and hospitalization caused by HF


Invasive therapy recommendations
Invasive Therapy Recommendations the National Institute for Health and Clinical Excellence Guideline

  • Patients who are at any stage of HF with left ventricular systolic dysfunction should be considered for an implantable cardioverter-defibrillator (ICD)

  • Criteria

    • Sustained ventricular tachycardia or non-sustained ventricular tachycardia that is inducible on electrophysiology testing if the left ventricular ejection fraction (LVEF) is less than 35%

    • QRS of duration of 120 ms or longer if the LVEF is less than 30%


Rehabilitation
Rehabilitation the National Institute for Health and Clinical Excellence Guideline

  • Moderate quality evidence shows that exercise rehab reduces hospital admissions for HF and increases long-term quality of life

  • GDG recommends supervised group exercise programs with psychological and educational components


Monitoring patients with hf
Monitoring Patients With HF the National Institute for Health and Clinical Excellence Guideline

  • Moderate quality evidence

    • Therapy guided by serum natriuretic peptide levels results in a reduction of hospitalizations due to HF

    • Therapy guided by serum natriuretic peptide levels reduces mortality in persons younger than 75

  • Cost effective analysis demonstrated that serial serum natriuretic peptide monitoring was cost effective when used by specialists

  • Significant heterogeneity of evidence for the use of telemonitoring in decreasing hospitalizations

    • GDG has no recommendation for telemonitoring


New evidence since the implementation of the 2010 nice guideline
New Evidence Since the Implementation of the 2010 NICE guideline

  • EMPHASIS-HF Study (Epleronone in Mild Patients Hospitalization and Survival Study in Heart Failure)

    • Significant reductions in hospitalization and mortality when epleronone therapy is started in patients hospitalized during the preceding 6 months or with persistent moderate elevation of serum natriuretic peptide levels (BNP≥250 ng/L)

  • SHIƒT (Systolic Heart Failure Treatment with the Iƒ Inhibitor Ivabradine Trial)

    • Ivabradine, Iƒ channel blocker in SA node, significantly reduces unplanned hospitalization and mortality in patients with HF due to left ventricular systolic dysfunction whose HR remains higher than 70bpm


Discussion
Discussion guideline

  • NICE guidelines are broadly consistent with other international guidelines (ESC and AHA)

  • Benefits

    • Earlier diagnosis

    • Better management

      • Decreased morbidity and mortality

    • Cost-effective



ad